Drug firm Lupin on Friday said it has received approval from the US health regulator to market generic Trientine Hydrochloride capsules used for treatment of Wilson's disease.
The company has received approval to market its Trientine Hydrochloride capsules USP, 250 mg, from the United States Food and Drug Administration (USFDA), Lupin said in a statement.
The product is a generic version ofBausch Health US LLC's Syprine capsules in the same strength, it added.
The capsules will be manufactured at Lupin's Nagpur (Unit 1) facility, Lupin said.
As per IQVIA MAT March 2020 data, Trientine Hydrochloride capsules USP had an annual sales of approximately USD 86 million in the US, it added.
The product is indicated in the treatment of patients suffering from Wilson's disease who are intolerant of penicillamine, the statement said.
Shares of Lupin Ltd were trading at Rs894.85per scrip on the BSE, up 1.03 per cent over previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app